Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 6
Submit an article Journal homepage
170
Views
15
CrossRef citations to date
0
Altmetric
Review

Antihypertensive therapy: special focus on drug interactions

Renke Maas Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. [email protected]
&
Rainer H Böger Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. [email protected]
Pages 549-579 | Published online: 03 Mar 2005

Bibliography

  • HAJJAR I, KOTCHEN TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA (2003) 290(2):199–206.
  • ••Most recent data on the prevalence ofhypertension in the US.
  • VASAN RS, BEISER A, SESHADRI S et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 287(8):1003–1010.
  • ••This study highlights the risk of beingtreated for hypertension.
  • HYMAN DJ, PAVLIK VN: Characteristics of patients with uncontrolled hypertension in the United States. N EngL J. Med. (2001) 345(7):479–486.
  • •Recent study that highlights the extent of uncontrolled hypertension in the US.
  • MATERSON BJ, REDA DJ, CUSHMAN WC et aL: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N EngL J. Med. (1993) 328(13):914–921. Erratum in: N EngL J Med. (1994) 330(23):1689.
  • BERLOWITZ DR, ASH AS, HICKEY EC et aL: Inadequate management of blood pressure in a hypertensive population. N EngL J Med. (1998) 339(27):1957–1963.
  • •Study highlighting the problem of inadequate blood pressure control.
  • AMAR J, VAUR L, PERRET M, BAILLEAU C, ETIENNE S, CHAMONTIN B: Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J. Hypertens. (2002) 20(4):779–784.
  • LANDI F, GAMBASSI G, LAPANE KL et al.: Comorbidity and drug use in cognitively impaired elderly living in long-term care. Dement. Geriatr. Cogn. Disorcl. (1998) 9(6):347–356.
  • •Evaluation of comorbidity and drug use in a large sample of elderly patients
  • MÜHLBERG W, PLATT D: Age-dependent changes of the kidneys: pharmacological implications. Gerontology (1999) 45(5):243–253.
  • •Reviews the impact of age-related changes of the kidneys on the pharmacokinetics of drugs.
  • PALMER BF: Current concepts: renal dysfunction complicating the treatment of hypertension. N EngL J. Med. (2002) 347(16):1256–1261.
  • KOHLER GI, BODE-BOGER SM, BUSSE R, HOOPMANN M, WELTE T, BOGER RH: Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int. J Gun. PharmacoL Ther. (2000) 38(1 0:504–413.
  • •This study links theoretically possible interactions and observed interactions.
  • CUSHMAN WC, REDA DJ, PERRY HM, WILLIAMS D, ABDELLATIF M, MATERSON BJ: Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch. Intern. Med. (2000) 160(6):825–831.
  • CARTER BL, LUND BC, HAYASE N, CHRISCHILLES E: The extent of potential antihypertensive drug interactions in a Medicaid population. Am. J. Hypertens. (2002) 15(11):953–957.
  • ••Dramatic data regarding the risk for druginteractions in a large hypertensive population.
  • LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279(15):1200–1205.
  • ••Landmark study on possible clinicalrelevance of ADRs.
  • LEVY M, KEWITZ H, ALTWEIN W, HILLEBRAND J, ELIAKIM M: Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur. j Gun. PharmacoL (1980) 17(1):25–31.
  • KELLY WN: Potential risks and prevention, Part 1: fatal adverse drug events. Am. J Health Syst. Pharm. (2001) 58(14):1317–1324.
  • SPECTOR R, VESELL ES: A rational approach to the selection of useful drugs for clinical practice. Pharmacology (2002) 65(2):57–61.
  • ••Summarises criteria for drug selection.
  • NEAFSEY PJ, SHELLMAN J: Misconceptions of older adults with hypertension concerning OTC medications and alcohol. Home. Healthc. Nurse (2002) 20(5):300–306.
  • NO AUTHORS LISTED: 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. Hypertens. (1999) 17(2):151–183.
  • GUIDELINES COMMITTEE: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21(6):1011–1053.
  • ••Most recent European guidelines for thetreatment of hypertension.
  • CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 289(19):2560–2572. Erratum in: JAMA (2003) 290(2):197.
  • ••Most recent US guidelines for thetreatment of hypertension.
  • RUZICKA M, LEENEN FH: Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs (2001) 61(7):943–954.
  • •Review of mono- versus combination therapy of hypertension.
  • BLACK HR, GRAFF A, SHUTE D et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J. Hum. Hypertens. (1997) 11(8):483–489.
  • DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360(9335):752–760.
  • PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582–1587.
  • COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N EngL J. Med. (2001) 345(23):1667–1675.
  • DOHERTY MM, CHARMAN WN: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. (2002) 41(4):235–253.
  • FINCH CK, CHRISMAN CR, BACIEWICZ AM, SELF TH: Rifarnpin and rifabutin drug interactions: an update. Arch. Intern. Med. (2002) 162(9):985–992.
  • WUTTKE H, RAU T, HEIDE R et cll.: Increased frequency of cytochrome P450 2D6 poor metabolisers among patients with metoprolol-associated adverse effects. Clin. PharmacoL Then (2002) 72(4):429–437.
  • •One of the first studies to demonstrate a link between genotype and adverse events in patients taking metoprolol.
  • FUNCK-BRENTANO C, TUREGON J, WOO SLEY RL, RODEN DL: Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J. PharmacoL Exp. Then (1989) 249(1):134–142.
  • XIE HG, KIM RB, WOOD AJ, STEIN CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. PharmacoL ToxicoL (2001) 41:815–850.
  • ••Reviews ethnic differences ofdrug metabolism.
  • KASHUBA AD, NAFZIGER AN, KEARNS GL et aL: Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics (1998) 8(5):403–410.
  • O'NEIL WM, GILFIX BM, MARKOGLOU N et aL: Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur. j Clin. PharmacoL (2000) 56(3):231–240.
  • THUMMEL KE, SHEN DD, PODOLLTD et aL: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. PharmacoL Exp. Ther. (1994) 271(1):549–556.
  • EAP CB, BERTEL-LAUBSCHER R, ZULLINO D, AMEY M, BAUMANN P: Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiaby (2000) 33(3):112–115.
  • LIN JH, LU AY: Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. PharmacoL ThxicoL (2001) 41:535–567.
  • PO AL, ZHANG WY: What lessons can be learnt from withdrawal of mibefradil from the market? Lancet (1998) 351(9119):1829–1830.
  • STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N EngL J Med. (2002) 346(7):539–540.
  • WEINSHILBOUM R: Inheritance and drug response. N EngL J. Med. (2003) 348(6):529–537.
  • ••Up-to-date review on the inheritance ofdrug response.
  • EVANS WE, MCLEOD HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N EngL J Med. (2003) 348(6):538–549.
  • ••Up-to-date review on pharmacogenomics.
  • ROSES AD: Pharmacogenetics and the practice of medicine. Nature (2000) 405(6788):857–865.
  • ••Comprehensive reviewof pharmacogenetics.
  • FLOCKHART DA, TANUS-SANTOS JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. (2002) 162(4):405–412.
  • ••Comprehensive review of antihypertensivedrugs and CYP450 interactions.
  • SINGH BN: Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. (1999) 37(3):213–255.
  • •A nice overview on the impact of food on clinical pharmacokinetics.
  • MELANDER A, MCLEAN A: Influence of food intake on presystemic clearance of drugs. am. Pharmacokinet. (1983) 8(4):286–296.
  • BAILEY DG, MALCOLM J, ARNOLD 0, SPENCE JD: Grapefruit juice-drug interactions. Br. J. Clin. PharmacoL (1998) 46(2):101–110.
  • •Reviews interactions of grapefruit juice and drugs.
  • SPAHN-LANGGUTH H, LANGGUTH P: Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. j Pharm. Sci. (2001) 12(4):361–367.
  • BAILEY DG, DRESSER GK, KREEFT JH, MUNOZ C, FREEMAN DJ, BEND JR: Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin. PharmacoL Ther. (2000) 68(5):468–477.
  • CHAN WK, DELUCCHI AB: Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Lifi Sci. (2000) 67(25):3103–3112.
  • XIN X, HE J, FRONTINI MG et aL: Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (2001) 38(5):1112–1117.
  • •A nice meta-analysis concerning the effects of alcohol on blood pressure.
  • BHARDWAI RK, GLAESER H, BECQUEMONT L, KLOTZ U, GUPTA SK, FROMM MF: Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. j PharmacoL Exp. Ther. (2002) 302(2):645–650.
  • RUSCHITZKA F, MEIER PJ, TURINA M et aL: Acute heart transplant rejection due to Saint John's wort. Lancet (2000) 355(9203):548–549.
  • DERGAL JM, GOLD JL, LAXER DA et aL: Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging (2002) 19(11):879–886.
  • FOSTER BC, VANDENHOEK S, TANG R, BUDZINSKI JW; KRANTIS A, LI KY: Effect of several Chinese natural health products of human cytochrome P450 metabolism. J. Pharm. Sci. (2002) 5(2): 185–189.
  • IOANNIDES C: Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica (2002) 32(6):451–478.
  • •Illustrative review of herb-drug interactions.
  • ROBY CA, ANDERSON GD, KANTOR E, DRYER DA, BURSTEIN AH: St John's Wort: effect on CYP3A4 activity. CIM. PharmacoL Ther. (2000) 67(5):451–457.
  • OBACH RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. PharmacoL Exp. Ther. (2000) 294(1):88–95.
  • DURR D, STIEGER B, KULLAK-UBLICK GA et al.: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Gun. Pharmacol. Ther. (2000) 68(6):598–604.
  • ERNST E: St John's Wort supplements endanger the success of organ transplantation. Arch. Surg (2002) 137(3):316–319.
  • DRESSER GK, SCHWARZ UI, WILKINSON GR, KIM RB: Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Pharmacol. Ther. (2003) 73(1):41–50.
  • HALLER CA, BENOWITZ NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl. J. Med. (2000) 343(25):1833–1838.
  • ZAHN KA, LI RL, PURUSSELL RA: Cardiovascular toxicity after ingestion of 'herbal ecstasy'. J. Emerg Med. (1999) 17(2):289–291.
  • HALLBERG P, KARLSSON J, KURLAND Let aL: The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Hypertens. (2002) 20(10):2089–2093.
  • YASAR U, ELIASSON E, DAHL ML et al.: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. (1999) 254(3):628–631.
  • YASAR U, FORSLUND-BERGENGREN C, TYB RING G et al.: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Pharmacol. Ther. (2002) 71(1):89–98.
  • FISCHER TL, PIEPER JA, GRAFF DW et al.: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. (2002) 72(3):238–246.
  • KATOH M, NAKAJIMA M, SHIMADA N, YAMAZAKI H, YOKOI T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur. J. Clin. Pharmacol. (2000) 55(11-12):843–852.
  • MINERS JO, REES DL, VALENTE L, VERONESE ME, BIRKETT DJ: Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism./ Pharmacol. Exp. Ther. (1995) 272(3):1076–1081.
  • DE GROOT MJ, ACKLAND MJ, HORNE VA, ALEX AA, JONES BC: A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. (1999) 42(20):4062–4070.
  • KUDO S, UCHIDA M, ODOMI M: Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur. J. Clin. Pharmacol. 1997 52(6):479–485.
  • GRAFF DW, WILLIAMSON KM, PIEPER JA et al.: Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Gun. Pharmacol. (2001) 41(1):97–106.
  • OLDHAM HG, CLARKE SE: In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug. Metab. Dispos. (1997) 25(8):970–977.
  • HERMANN DJ, KROL TF, DUKES GE et al.: Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imiprarnine. J. Clin. Pharmacol. (1992) 32(2):176–183.
  • MANGRELLA M, ROSSI F, FICI F, ROSSI F: Pharmacology of nebivolol. Pharmacol. Res. (1998) 38(6):419–431.
  • BROLY F, LIBERSA C, LHERMITTE M, DUPUIS B: Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem. Pharmacol. (1990) 39(6):1045–1053.
  • GEUN SHINY, BOLTON JL, VAN BREEMEN RB: Screening drugs for metabolic stability using pulsed ultrafiltration mass spectrometry. Comb. Chem. High Throughput Screen. (2002) 5(1):59–64.
  • ZHOU HH, ANTHONY LB, RODEN DM, WOOD AJ: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin. Pharmacol. Ther. (1990) 47(6):686–693.
  • EDEKI TI, HE H, WOOD AJ: Pharrnacogenetic explanation for excessive a3-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA (1995) 274(20):1611–1613.
  • ZAIDENSTEIN R, SOBACK S, GIPS M et al.: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther. Drug Monit. (2001) 23(4):369–373.
  • YUN CH, LEE HS, LEE H, RHO JK, JEONG HG, GUENGERICH FP: Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. (1995) 23(2):285–289.
  • SUTTON D, BUTLER AM, NADIN L, MURRAY M: Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol. Exp. Ther. (1997) 282(1):294–300.
  • CHRISTENSEN H, ASBERG A, HOLMBOE AB, BERG KJ: Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur. J. Clin. Pharmacol. (2002) 58(8):515–520.
  • MOUSA O, BRATER DC, SUNBLAD KJ, HALL SD: The interaction of diltiazem with simvastatin. Gun. Pharmacol. Ther. (2000) 67(3):267–274.
  • •Interesting study demonstrating a significant effect of diltiazem on simvastatin plasma concentration.
  • KAESER YA, BRUNNER F, DREWE J, HAEFELI WE: Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am. J Health Syst. Pharm. (1998) 55(22):2417–2418.
  • TRACY TS, KORZEKWA KR, GONZALEZ FJ, WAINER IW: Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J Clin. Pharmacol. (1999) 47(5):545–552.
  • GUENGERICH FE BRIAN WR, IWASAKI M, SARI MA, BAARNHIELM C, BERNTSSON P: Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450 IIIA4. J. Med. Chem. (1991) 34(6):1838–1844.
  • VINCENT J, HARRIS SI, FOULDS G, DOGOLO LC, WILLAVIZE S, FRIEDMAN HL: Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynarnics of arnlodipine. Br. J. Clin. Pharmacol. (2000) 50:455–463.
  • LOWN KS, BAILEY DG, FONTANA RJ et al.: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. (1997) 99(10):2545–2553.
  • BAILEY DG, BEND JR, ARNOLD JM, TRAN LT, SPENCE JD: Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin. Pharmacol Then (1996) 60(1):25–33.
  • KLOTZ U: Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung (2002) 52(3): 155–161.
  • BAILEY DG, SPENCE JD, MUNOZ C, ARNOLD JM: Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337(8736):268–269.
  • NARITOMI Y, TERASHITA S, KIMURA S, SUZUKI A, KAGAYAMA A, SUGIYAMA Y: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. (2001) 29(10):1316–1324.
  • BAILEY DG, ARNOLD JM, STRONG HA, MUNOZ C, SPENCE JD: Effect of grapefruit juice and naringen on nisoldipine pharmacokinetics. Pharmacol Ther. (1993) 54(6):589–594.
  • SOONS PA, VOGELS BA, ROOSEMALEN MC et al: Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Pharmacol Ther. (1991) 50(4):394–403.
  • TAKARA K, KAKUMOTO M, TANIGAWARA Y, FUNAKOSHI J, SAKAEDA T, OKUMURA K: Interaction of digoxin with antihypertensive drugs via MDR1. Lifi Sci. (2002) 70(13):1491–1500.
  • TERAO T, HISANAGA E, SAT Y, TAMAI I, TSUJI A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm. Pharmacol (1996) 48(10):1083–1089.
  • CHIOU WL, CHUNG SM, WU TC, MA C: A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J Gun. Pharmacol Ther. (2001) 39(3):93–101.
  • WESTPHAL K, WEINBRENNER A, GIESSMANN T et al: Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Gun. Pharmacol Ther. (2000) 68(1):6–12.
  • VAN KALKEN CK, VAN DER HOEVEN JJ, DE JONG J et al: Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur. J Cancer (1991) 27(6):739–744.
  • LINN SC, VAN KALKEN CK, VAN TELLINGEN et al: Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. j Gun. Oncol (1994) 12(4):812–819.
  • KATOH M, NAKAJIMA M, YAMAZAKI H, YOKOI T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm. Res. (2000) 17(10):1189–1197. Erratum in: Pharm. Res. (2001) 18(5):718.
  • PAULI-MAGNUS C, VON RICHTER O, BURK O et al: Characterization of the major metabolites of veraparnil as substrates and inhibitors of P-glycoprotein. Pharmacol Exp. Ther. (2000) 293(2):376–382.
  • AYRTON A, MORGAN P: Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica (2001) 31(8-9):469–497.
  • ••Reviews the role of transport proteins indrug absorption, distribution and excretion.
  • WIESFELD AC, REMME WJ, LOOK MP, KRUIJSSEN DA, VAN HOOGENHUYZE DC: Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol. Am. J. Cardiol (1992) 70(10:997–1003.
  • SAGIE A, STRASBERG B, KUSNIECK J, SCLAROVSKY S: Symptomatic bradycardia induced by the combination of oral diltiazem and P-adrenoreceptor blockers. Cardiol (1991) 14(0314–316.
  • ROSENKRANZ B, LEDERMANN H, FROLICH JC: Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. J. Cardiovasc. Pharmacol (1986) 8(5):943–949.
  • MISRA M, THAKUR R, BHANDARI K: Sinus arrest caused by atenolol-veraparnil combination. Clin. Cardiol (1987) 10(6):365–367.
  • BAILEY DG, CARRUTHERS SG: Interaction between oral verapamil and P-blockers during submaximal exercise: relevance of ancillary properties. Pharmacol Ther. (1991) 49(4):370–376.
  • ROBSON RH, VISHWANATH MC: Nifedipine and 13-blockade as a cause of cardiac failure. Br. Med. J (Clin. Res. Ed.) (1982) 284(6309):104.
  • YATSUKA YI, TSUTSUMI K, KOTEGAWA T, NAKAMURA K, NAKANO S, NAKATSUKA K: Interaction between timolol eyedrops and oral nicardipine or oral diltiazem in healthy Japanese subjects. Eur. j Gun. Pharmacol (1998) 54(2):149–154.
  • CUMMINGS DM, VLASSES PH: Antihypertensive drug withdrawal syndrome. Drug Intell Gun. Pharm. (1982) 16(11):817–822.
  • BAILEY RR, NEALE TJ: Rapid clonidine withdrawal with blood pressure overshoot exaggerated by 13-blockade. Br. Med. J. (1976) 1(6015):942–943.
  • NIES AS, SHAND DG: Hypertensive response to propranolol in a patient treated with methyldopa - a proposed mechanism. Clin. Pharmacol Ther. (1973) 14(5):823–826.
  • BOUTITIE F, BOISSEL JP, CONNOLLY SJ et al.: Amiodarone interaction with P-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circu/ation (1999) 99(17):2268–2275.
  • ABATE MA, LAYNE RD, NEELY JL, D'ALESSANDRI R: Effect of naproxen and sulindac on blood pressure response to atenolol. DICP (1990) 24(9):810–813.
  • RADACK KL, DECK CC, BLOOMFIELD SS: Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann. Intern. Med. (1987) 107(5):628–635.
  • DURAO V, PRATA MM, GONCALVES LM: Modification of antihypertensive effect of P-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet (1977) 2(8046):1005–1007.
  • MAGNUSSON J, THULIN T, WERNER O, JARHULT J, THOMSON D: Haemodynarnic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery. Br. J. Anaesth. (1986) 58(3):251–260.
  • ZAUGG M, TAGLIENTE T, LUCCHINETTI E et al.: Beneficial effects from P-adrenergic blockade in elderly patients undergoing noncardiac surgery. Anesthesiology (1999) 91(6):1674–1686.
  • ZHANG C, BANTING DW, GELB AW, HAMILTON JT: Effect of P-adrenoreceptor blockade with nadolol on the duration of local anesthesia. J. Am. Dent. Assoc. (1999) 130(12):1773–1780.
  • PITTS WR, LANGE RA, CIGARROA JE, HILLIS LD: Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog. Cardiovasc. Dis. (1997) 40(1):65–76.
  • LANGE RA, HILLIS LD: Cardiovascular complications of cocaine use. N Engl. J. Med. (2001) 345(5):351–358. Erratum in: N. Engl. J Med. (2001) 345(19):1432.
  • CONRAD KA, BYERS JM III, FINLEY PR, BURNHAM L: Lidocaine elimination: effects of metoprolol and of propranolol. Gun. Pharmacol. Then (1983) 33(2):133–138.
  • JORDO L, JOHNSSON G, LUNDBORG P, REGARDH CG: Pharmacokinetics of lidocaine in healthy individuals pretreated with multiple doses of metoprolol. Int. J Gun. Pharmacol. Ther. Taxied. (1984) 22(6):312–315.
  • ELLIOT HL, MEREDITH PA, MCNALLY C, REID JL: The interactions between nisoldipine and two P-adrenoceptor antagonists - atenolol and propranolol. Br. J. Clin. Pharmacol. (1991) 32(3):379–385.
  • BAUER LA, HORN JR, MAXON MS, EASTERLING TR, SHEN DD, STRANDNESS DE Jr: Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition. j Gun. Pharmacol. (2000) 40(5):533–543.
  • ZATUCHNI J: Bradycardia and hypotension after propranolol HC1 and verapamil. Heart Lung (1985) 14(1):94–95.
  • BONDE J, PEDERSEN LE, ANGELO HR, TRAP-JENSEN J, SVENDSEN TL, KAMPMANN JP: Haemodynamic effects and kinetics of concomitant intravenous disopyrarnide and atenolol in patients with ischaemic heart disease. Eur. J. Clin. Pharmacol. (1986) 30(2):161–166.
  • SCHÄFER-KORTING M, KIRCH W, AXTHELM T, KOHLER H, MUTHSCHLER E: Atenolol interaction with aspirin, allopurinol, and arnpicillin. Pharmacol. Ther. (1983) 33(3):283–288.
  • MANTYLA R, ALLONEN H, KANTO J, KLEIMOLA T, SELLMAN R: Effect of food on the bioavailability of labetalol. Br. J. Clin. Pharmacol. (1980) 9(4):435–437.
  • MUTSCHLER E, SPAHN H, KIRCH W: The interaction between H2-receptor antagonists and P-adrenoceptor blockers. Br. J. Clin. Pharmacol. (1984) 17\(Suppl. 1):S51–S57.
  • LAM YW; GAEDIGK A, ERESHEFSKY L, ALFARO CL, SIMPSON J: CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy (2002) 22(8):1001–1006.
  • BELPAIRE FM, WIJNANT P, TEMMERMAN A, RASMUSSEN BB, BROSEN K: The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur. j Gun. Pharmacol. (1998) 54(3):261–264.
  • LESKO LJ: Pharmacokinetic drug interactions with amiodarone. Pharmacokinet. (1989) 17(2):130–140.
  • JAFFE R, LIVSHITS T, BURSZTYN M: Adverse interaction between clonidine and verapamil. Ann. Pharmacother. (1994) 28(7-8):881–883.
  • HOLTZMAN JL, FINLEY D, MOTTONEN L et al.: The pharmacodynarnic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin. Pharmacol. Ther. (1989) 46(1):26–32.
  • VERSCHRAAGEN M, KOKS CH, SCHELLENS JH, BEIJNEN JH: P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. (1999) 40(4):301–306.
  • HEEREY A, BARRY M, RYAN M, KELLY A: The potential for drug interactions with statin therapy in Ireland. Ir. J. Med. Sci. (2000) 169(3):176–179.
  • BOGER RH: Drug interactions of the statins and consequences for drug selection. Int. J. Clin. Pharmacol. Ther. (2001) 39(9):369–382.
  • •Reviews practical consequences of differences in drug metabolism for the selection of statins.
  • CORSINI A, BELLOSTA S, BAETTA R, FUMAGALLI R, PAOLETTI R, BERNINI F: New insights into the pharmacodynarnic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84(3):413–428.
  • •Reviews pharmacogenetic considerations for the selection of statins.
  • KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64(2):177–182.
  • KUSUS M, STAPLETON DD, LERTORA JJ, SIMON EE, DREISBACH AW: Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am. J. Med. Sci. (2000) 320(6):394–397.
  • LEWIN JJ III, NAPPI JM, TAYLOR MH: Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann. Pharmacother. (2002) 36(10):1546–1549.
  • NO AUTHORS LISTED: Product information. Zocor. Merck.
  • NO AUTHORS LISTED: Product information. Mevacor. Merck.
  • CHONG PH, SEEGER JD, FRANKLIN C: Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med. (2001) 111(5):390–400.
  • JONES TE, MORRIS RG, MATHEW TH: Diltiazem-cyclosporin pharmacokinetic interaction - dose-response relationship. Br. J. Clin. Pharmacol. (1997) 44(5):499–504.
  • JACOB LP, MALHOTRA D, CHAN L, SHAPIRO JI: Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil. Am. J Kidney Dis. (1999) 33(2):301–303.
  • ASBERG A, CHRISTENSEN H, HARTMANN A et aL: Pharrnacokinetic interactions between microernulsion formulated cyclosporine A and diltiazem in renal transplant recipients. Eur. Clin. Pharmaca (1999) 55(5):383–387.
  • MCDONALD SP, RUSS GR: Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney Int. (2002) 61(6):2259–2265.
  • NO AUTHORS LISTED: Product information. Prograf. Tacrolimus. Fujisawa Healthcare, Inc.
  • SEIFELDIN RA, MARCOS-ALVAREZ A, GORDON FD, LEWIS WD, JENKINS RL: Nifedipine interaction with tacrolimus in liver transplant recipients. Ann. Pharmacother. (1997) 31(5):571–572.
  • ROSENTHAL T, EZRA D: Calcium antagonists. Drug interactions of clinical significance. Drug Saf (1995) 13(3):157–187.
  • ••A very detailed review of drug interactionsinvolving calcium antagonists.
  • PLOSKER GL, FOSTER RH: Eprosartan: a review of its use in the management of hypertension. Drugs (2000) 60(1):177–201.
  • SHARPE M, JARVIS B, GOA KL: Telmisartan: a review of its use in hypertension. Drugs (2001) 61(10):1501–1529.
  • SEE S: Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin. Pharmacother. (2001) 2(11):1795–1804.
  • KJELDSEN SE, DAHLOF B, DEVEREUX RB et al; LIFE (LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION) STUDY GROUP: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 288 (12):1491–1498.
  • WARNER GT, JARVIS B: Olmesartan medoxomil. Drugs (2002) 62(9):I345–1353. Discussion 1354–1356.
  • TRENKWALDER P: Combination therapy with AT(1)-receptor blockers. J. Hum. Hypertens. (2002) 16\(Suppl. 3):5I7–525.
  • CHIU AG, KROWIAK EJ, DEEB ZE: Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope (2001) 111(10):1729–1731.
  • STERGIOU GS, SKEVA II, BAIBAS NM et al.: Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J. Cardiovasc. Pharmacol. (2000) 35(6):937–941.
  • KONSTAM MA: Comment - Val-HeFT and angiotensin-receptor blockers in perspective: a tale of the blind man and the elephant. J. Card. Fail. (2002) 8(2):56–58.
  • CAMPBELL DJ: Valsartan in chronic heart failure. N Engl. J. Med. (2002) 346(I5):1173–1174.
  • CAYLEY WE Jr: Valsartan in chronic heart failure. N Engl. J. Med. (2002) 346(I5):1173–1174.
  • MAILLARD JO, DESCOMBES E, FELLAY G, REGAMEY C: Repeated transient anuria following losartan administration in a patient with a solitary kidney. Ren. Fail. (2001) 23(1):143–147.
  • CONLIN PR, MOORE TJ, SWARTZ SL et al.: Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension (2000) 36(3):46I-465.
  • FOGARI R, ZOPPI A, CARETTA R, VEGLIO F, SALVETTI A: Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J. Hypertens. (2002) 20(5):1007–1014.
  • POLLOCK DM, MORSING P: Combined treatment with ibuprofen and the ATI receptor antagonist candesartan in young spontaneously hypertensive rats. J Am. Soc. Nephrol. (1999) 10\(Suppl. 11):5116–5119.
  • ZWANGER P, MARCUSE A, BOERNER RJ, WALTHER A, RUPPRECHT R: Lithium intoxication after administration of ATI blockers. Clin. Psychiatry (2001) 62(3):208–209.
  • BLANCHE P, RAYNAUD E, KEROB D, GALEZOWSKI N: Lithium intoxication in an elderly patient after combined treatment with losartan. Eur. j Clin. Pharmacol. (1997) 52(6):50I.
  • TAAVITSAINEN P, KIUKAANIEMI K, PELKONEN O: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. j Clin. Pharmacol. (2000) 56(2):135–140.
  • FICHTENBAUM CJ, GERBER JG: Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. (2002) 41(14):1195–1211.
  • SCRIPTURE CD, PIEPER JA: Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. (2001) 40(4):263–281.
  • KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. (1997) 62(4):417–425.
  • ZAIDENSTEIN R, SOBACK S, GIPS M et al.: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Then Drug Monit. (2001) 23(4):369–373.
  • MARINO MR, VACHHARAJANI NN: Drug interactions with irbesartan. Clin. Pharmacokinet. (2001) 40(8):605–614.
  • BROOKMAN LJ, ROLAN PE, BENJAMIN IS et al.: Pharmacokinetics of valsartan in patients with liver disease. Clin. Pharmacol. Ther. (1997) 62(3):272–278.
  • TAAVITSAINEN P, KIUKAANNIEMI K, PELKONEN O: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. (2000) 56(2):135–140.
  • ISRAILI ZH: Clinical pharmacokinetics of angiotensin II (ATI) receptor blockers in hypertension. J Hum. Hypertens. (2000) 14\(Suppl. 1):573–586.
  • FISCHER TL, PIEPER JA, GRAFF DW: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. (2002) 72(3):238–246.
  • ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP. THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288(23):298I-2997.
  • ••A must read for all interested in thetreatment of hypertension.
  • MALACCO E, PIAZZAS, CAREZZA R, DI SOMMA S, MUGELLINI A, BERTOCCHI F: Comparison of benazepril-arnlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int. J Clin. Pharmacol. Ther. (2002) 40:263–269.
  • PRISANT LM: Fixed low-dose combination in first-line treatment of hypertension. Hypertens. (2002) 20\(Suppl. 1):S11–S19.
  • TANNEN RL: Diuretic-induced hypokalemia. Kidney Int. (1985) 28(6):988–1000.
  • BRATER DC: Drug-induced electrolyte disorders and use of diuretics. In: Fluids and electrolytes (3rd edn). Kokko JP, Tannen RL (Eds), WB Saunders, Philadelphia, USA (1996):693–728.
  • •Further details on diuretics and electrolyte disorders.
  • COOPER HA, DRIES DL, DAVIS CE, SHEN YI,, DOMANSKI MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100(12):1311–1315.
  • •Interesting analysis of arrhythmic deaths associated with the use of non-potassium-sparing diuretics.
  • FRANSE LV, PAHOR M, DI BARI M, SOMES GW, CUSHMAN WC, APPLEGATE WB: Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension (2000) 35(5):1025–1030.
  • GIRON MS, WANG HX, BERNSTEN C, THORSLUND M, WINBLAD B, FASTBOM J: The appropriateness of drug use in an older nondemented and demented population. J. Am. Geriatr. Soc. (2001) 49(3):277–283.
  • VAN DIJK KN, DE VRIES CS, VAN DEN BERG PB, BROUWERS JR, DE JONG-VAN DEN BERG LT: Drug utilisation in Dutch nursing homes. Eur. j Clin. Pharmacol. (2000) 55(10):765–771.
  • RUDOLF J, WURKER M, NEVELING M, GROND M, HAUPT WF, HEISS WD: Hypokalemic paralysis in furosemide therapy and simultaneous laxative abuse. Med. Klin. (1999) 94(7):391–394.
  • MERLO J, LIEDHOLM H, LINDBLAD U et al.: Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross-sectional study. Br. Med. J (2001) 323(7310):427–428.
  • •Study provides evidence for the frequent combination of potassium supplements and potassium-sparing diuretics.
  • SCHEPKENS H, VANHOLDER R, BILLIOUW JM, LAMEIRE N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am. J Med. (2001) 110(6):438–441.
  • SISCOVICK DS, RAGHUNATAN TE, PSATY BM et al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med. (1994) 330(26):1852–1857.
  • HOUSTON MC: Nonsteroidal anti-inflammatory drugs and antihypertensives. Am. J. Med. (1991) 90(5A):425–475.
  • POPE JE, ANDERSON JJ, FELSON DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. (1993) 153(4):477–484.
  • GURWITZ JH, EVERITT DE, MONANE M et al.: The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J. Gerontol. A. Biol. Sci. Med. Sci. (1996) 51(2):M74–M79.
  • HEERDINK ER, LEUFKENS HG, HERINGS RM, OTTERVANGER JP, STRICKER BH, BAKKER A: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med. (1998) 158(10):1108–1112.
  • ZANCHETTI A, HANSSON L, LEONETTI Get al.: Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J. Hypertens. (2002) 20(5):1015–1022.
  • KOOPMANS PP, THIEN T, THOMAS CM, VAN DEN BERG RJ, GRIBNAU FW: The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br. J. Clin. Pharmacol. (1986) 21(4):417–423.
  • THAKUR V, COOK ME, WALLIN JD: Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflarnmatory drugs. Am. J Hypertens. (1999) 12(9 Pt 1):925–928.
  • MENE P, PUGLIESE F, PATRONO C: The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin. Nephrol. (1995) 15(3):244–252.
  • WILSON TW, MCCAULEY FA, WELLS HD: Effects of low-dose aspirin on responses to furosemide. j Clin. Pharmacol. (1986) 26(2):100–105.
  • HOUSTON MC, WEIR M, GRAY J et aL: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by veraparnil. Arch. Intern. Med. (1995) 155(10):1049–1054.
  • CELTS H, THIJS L, STAESSEN JA et al.: Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial. J. Hum. Hypertens. (2001) 15(9):613–618.
  • BATES DE, BEAUMONT SJ, BAYLIS BW: Ototoxicity induced by gentarnicin and furosemide. Ann. Pharmacother. (2002) 36(3):446–451.
  • SMITH CR, LIETMAN PS: Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob. Agents Chemother. (1983) 23(1):133–137.
  • METHA BR, ROBINSON BH: Lithium toxicity induced by triarnterene-hydrochlorothiazide. Postgrad. Med. J (1980) 56(661):783–784.
  • SPROULE BA, HARDY BG, SHULMAN KI: Differential pharmacokinetics of lithium in elderly patients. Drugs Aging (2000) 16(3):165–177.
  • NURNBERGER JI Jr: Diuretic-induced lithium toxicity presenting as mania. Nerv. Ment. Dis. (1985) 173(5):316–318.
  • MANOUVRIER J, SAGOT M, CARON C et al.: Nine cases of torsade de pointes with bepridil administration. Am. Heart J. (1986) 111(5): 1005–1007.
  • NO AUTHORS LISTED: Product information. Inapsine. Akorn, Inc.
  • NO AUTHORS LISTED: Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Br. Med. J. (1989) 298(6671):424–430.
  • NO AUTHORS LISTED: Product information. L-Polamidon. Aventis Pharma.
  • BRIDOUX F, HAZZAN M, PALLOT JL et al.: Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial. Transplant. (1992) 7(2):100–104.
  • NO AUTHORS LISTED: Product information. Hydrocortison Hoechst. Hoechst AG.
  • BARTOLI E, ARRAS S, FAEDDA R, SOGGIA G, SATTA A, OLMEO NA: Blunting of furosemide diuresis by aspirin in man. J. Clin. Pharmacal. (1980) 20(7):452–458.
  • DE KLERK GJ, NIEUWENHUIS MG, BEUTLER JJ: Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. Br. Med. J (1997) 314(7082):731–732.
  • BRUMMETT RE, BENDRICK T, HIMES D: Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. J. Clin. Pharmacal. (1981) 21(11–12 Pt 2):628–636.
  • KAKA JS, LYMAN C, KILARSKI DJ: Tobramycin-furosemide interaction. Drug Intell. Gun. Pharm. (1984) 18(3):235–238.
  • NEUVONEN PJ, KIVISTO K, HIRVISALO EL: Effects of resins and activated charcoal on the absorption of digoxin, carbarnazepine and frusemide. Br J GLin. Pharmacal. (1988) 25(2):229–233.
  • HUNNINGHAKE DB, HIBBARD DM: Influence of time intervals for cholestyrarnine dosing on the absorption of hydrochlorothiazide. Gun. Pharmacal. Ther. (1986) 39(3):329–334.
  • FINE A, HENDERSON IS, MORGAN DR, TILSTONE WJ: Malabsorption of frusemide caused by phenytoin. Br Med. J (1977) 2(6094):1061–1062.
  • MCCRINDLE JL, LI KAM WA TC, BARRON W, PRESCOTT LF: Effect of food on the absorption of frusemide and bumetanide in man. Br. J Pharmacal. (1996) 42(6):743–746.
  • KAWAGUCHI A, SUGIMOTO K, OHMORI M et al.: Furosernide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology. Pharmacal. Ther. (2001) 69(4):232–237.
  • DIXEY JJ, NOORMOHAMED FH, PAWA JS, LANT AF, BREWERTON DA: The influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to and kinetics of piretanide in man. Clin. Pharmacal. Ther. (1988) 44(5):531–539.
  • WALDORFF S, ANDERSEN JD, HEEBOLL-NIELSEN N et al.: Spironolactone-induced changes in digoxin kinetics. Clin. Pharmacal. Ther. (1978) 24(2):162–167.
  • NO AUTHORS LISTED: American Hospital Formulary Service. American Society of Hospital Pharmacists, Washington DC, USA (1997).
  • NO AUTHORS LISTED: Product information. Prograf. Fujisawa.
  • CHIU TF, BULLARD MJ, CHEN JC, LIAW SJ, NG CJ: Rapid life-threatening hyperkalemia after addition of amiloride HC1/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann. Emerg. Med. (1997) 30(5):612–615.
  • PACKER M, LEE WH, KESSLER PD, MEDINA N, YUSHAK M, GOTTLIEB SS: Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am. Coll. Cardial. (1987) 10(4):837–844.
  • PACKER M, LEE WH, MEDINA N, YUSHAK M, KESSLER PD, GOTTLIEB SS: Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am. J. Med. (1987) 82(6):1119–1126.
  • REMME WJ, SWEDB ERG K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (2001) 22(17):1527–1560.
  • ••State-of-the-art review of the treatment ofheart failure.
  • MOTWANI JG, STRUTHERS AD: Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II. Br. J. Clin. Pharmacal. (1992) 34(1):25–31.
  • MCLAY JS, MCMURRAY JJ, BRIDGES AB, FRASER CG, STRUTEHRS AD: Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am. Heart J. (1993) 126(4):879–886.
  • CLELAND JG, GILLEN G, DARGIE HJ: The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur. Heart J. (1988) 9(2):132–141.
  • LEARY WP, REYES AJ, VAN DER BYL K: Effects of angiotensin-converting enzyme inhibitors on urinary excretions: interactions with diuretics. Am. J Med. (1992) 92(4B):S64–S68.
  • BERTRAND M, GODET G, MEERSSCHAERT K, BRUN L, SALCEDO E, CORIAT P: Should the angiotensin II antagonists be discontinued before surgery? Anesth. Analg. (2001) 92(1):26–30.
  • WILLIAMS NE: Profound bradycardia and hypotension following spinal anaesthesia in a patient receiving an ACE inhibitor: an important 'drug' interaction? Eur. J. Anaesthesia. (1999) 16(10:796–798.
  • CORIAT P, RICHER C, DOURAKI T et al.: Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology (1994) 81(2):299–307.
  • HALL D, ZEITLER H, RUDOLPH W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am. Coll. Cardial. (1992) 20(7):1549–1555.
  • NGUYEN KN, AURSNES I, KJEKSHUS J: Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II a(CONSENSUS II). Am. J Cardial. (1997) 79(2):115–119.
  • NAWARSKAS JJ, TOWNSEND RR, CIRIGLIANO MD, SPINLER SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am. J Hypertens. (1999) 12(8 Pt 1):784–789.
  • GUAZZI M, PONTONE G, AGOSTONI P: Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am. Heart J. (1999) 138(2 Pt 0:254–260.
  • AHMED A: Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? J. Am. Geriatr. Soc. (2002) 50(7):1293–1296.
  • SPAULDING C, CHARBONNIER B, COHEN-SOLAL A et al.: Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation (1998) 98(8):757–765.
  • HAUSBERG M, BARENBROCK M, HOHAGE H, MULLER S, HEIDENREICH S, RAHN KH: ACE inhibitor versus P-blocker for the treatment of hypertension in renal allograft recipients. Hypertension (1999) 33(3):862–868.
  • MURRAY BM, VENUTO RC, KOHLI R, CUNNINGHAM EE: Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine. Am. J Kidney Dis. (1990) 16(1):66–69.
  • BALDWIN CM, SAFFERMAN AZ: A case of lisinopril-induced lithium toxicity. DICP (1990) 24(10):946–947.
  • ABRAHAM G, GRUNBERG B, GRATZ S: Possible interaction of clozapine and lisinopril. Am. J Psychiatry (2001) 158(6):969.
  • SONG JC, WHITE CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin-converting enzyme inhibitors: an update. Clin. Pharmacokinet. (2002) 41(3):207–224.
  • •An update on newer ACE inhibitors.
  • MIGNAT C, UNGER T: ACE inhibitors. Drug interactions of clinical significance. Drug Saf (1995) 12(5):334–347.
  • SHIONOIRI H: Pharmacokinetic drug interactions with ACE inhibitors. Pharmacokinet. (1993) 25(1):20–58.
  • •An older but nevertheless useful review on ACE inhibitors.
  • FINLEY PR, O'BRIEN JG, COLEMAN RW: Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. j Gun. Pychopharmacol. (1996) 16(1):68–71.
  • GOSSMANN J, THURMANN P, BACHMANN T et al.: Mechanism of angiotensin-converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int. (1996) 50(3):973–978.
  • MESSERLI FH: Doxazosin and congestive heart failure. J Am. Coll. Cardiol. (2001) 38(5):1295–1296.
  • •Short review of safety concerns regarding the use of a-adrenergic blockers in cardiovascular disease.
  • AKDUMAN B, CRAWFORD ED: Terazosin, doxazosin, and prazosin: current clinical experience. Urology (2001) 58(6 Suppl. 1):49–54.
  • •Review concerning the side effects of a-adrenergic blockers.
  • SICA DA: Doxazosin and congestive heart failure. Congest. Heart Fail. (2002) 8(3):178–184.
  • KAWANO Y, ABE H, KOJIMA S, TAKISHITA S, OMAE T: Interaction of alcohol and an arblocker on ambulatory blood pressure in patients with essential hypertension. Am. J Hypertens. (2000) 13(3):307–312.
  • •Illustrative study concerning the interaction of prazosin and alcohol.
  • ELLIOT HL, MEREDITH PA, CAMPBELL L, REID JL: The combination of prazosin and verapamil in the treatment of essential hypertension. Clin. Pharmacol. Ther. (1988) 43(5):554–560.
  • ELLIOT HL, MCLEAN K, SUMMER DJ, MEREDITH PA, REID JL: Immediate cardiovascular responses to oral prazosin-effects of concurrent I3-blockers. Clin. Pharmacol. Ther. (1981) 29(3):303–309.
  • ELLIOTT HL, PASANISI F, MEREDITH PA, REID JL: Acute hypotensive response to nifedipine added to prazosin. Br. Med. J (1984) 288(6412):238–239.
  • PASASINI F, ELLIOTT HL, MEREDITH PA, MCSHARRY DR, REID JL: Combined a adrenoceptor antagonism and calcium channel blockade in normal subjects. Clin. Pharmacol. Ther. (1984) 36(6):716–723.
  • ZAIDENSTEIN R, DISHI V et al.: The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur. j Clin. Pharmacol. (1998) 54(4):337–340.
  • HO PC, GHOSE K, SAVILLE D, WAN WIMOLRUK S: Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur. j Clin. Pharmacol. (2000) 56(9-10):693–698.
  • FUHR U, MULLER-PELTZER H, KERN R et al.: Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur. j Clin. Pharmacol. (2002) 58(1):45–53.
  • JOSEFSSON M, ZACKRISSON AL, AHLNER J: Effect of grapefruit juice on the pharmacokinetics of arnlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. (1996) 51(2):189–193.
  • KOSUGE K, JUN Y, WATANABE H et al.: Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab. Dispos. (2001) 29(10):1284–1289.
  • BINDER EF, CAYABYAB L, RITCHIE DJ, BIRGE SJ: Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Arch. Intern. Med. (1991) 151(2):373–374.
  • WAYNE VS, HARPER RW, LAUFER E, FEDERMAN J, ANDERSON ST, PTI"I A: Adverse interaction betweenI3-adrenergic blocking drugs and verapamil - report of three cases. Aust. NZ J Med. (1982) 12(4):285–289.
  • TATEISHI T, NAKASHIMA H, SHITOU T et al.: Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur. j Clin. Pharmacol. (1989) 36(1):67–70.
  • MAOZ E, GROSSMAN E, THALER M, ROSENTHAL T: Carbarnazepine neurotoxic reaction after administration of diltiazem. Arch. Intern. Med. (1992) 152(12):2503–2504.
  • EIMER M, CARTER BL: Elevated serum carbarnazepine concentrations following diltiazem initiation. Drug Intell. Clin. Pharm. (1987) 21(4):340–342.
  • YASUI-FURUKORI N, TATEISHI T: Carbamazepine decreases antihypertensive effect of nilvadipine. j Clin. Pharmacol. (2002) 42(1):100–103.
  • BAHLS FH, OZUNA J, RITCHIE DE: Interactions between calcium channel blockers and the anticonvulsants carbarnazepine and phenytoin. Neuro/ogy (1991) 41(5):740–742.
  • ANDREJAK M, HARY L, ANDREJAK MT, LESBRE JP: Diltiazem increases steady state digoxin serum levels in patients with cardiac disease. Clin. Pharmacol. (1987) 27(12):967–970.
  • KUHLMAN J: Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin. Clin. PharmacoL Ther. (1985) 38(6):667–673.
  • SUEMATSU F, YUKAWA E, YUKAWA M et al.: Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis. Biopharm. Drug Dispos. (2002) 23(5):173–181.
  • KLEIN HO, LANG R, WEISS E et al.: The influence of verapamil on serum digoxin concentration. Circulation (1982) 65(5):998–1003.
  • KIRCH W, STENZEL J, DYLEWICS P, HUTT HJ, SANTOS SR, OHNHAUS EE: Influence of nisoldipine on haemodynarnic effects and plasma levels of digoxin. Br. J. Clin. Pharmacol. (1986) 22(2):155–159.
  • BACKMAN JT, OLKKOLA KT, ARANKO K, HIMBERG JJ, NEUVONEN PJ: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br. J. Clin. Pharmacol. (1994) 37(3):221–225.
  • DRESSER GK, BAILEY DG, CARRUTHERS SG: Grapefruit juice-felodipine interaction in the elderly. Clin. PharmacoL Then (2000) 68(1):28–34.
  • GOLDSCHMIDT N, AZAZ-LIVSHITS T, GOTSMAN, NIR-PAZ R, BEN-YEHUDA A, MUSZKAT M: Compound cardiac toxicity of oral erythromycin and veraparnil. Ann. Pharmacother. (2001) 35(11):1396–1369.
  • BAILEY DG, BEND JR, ARNOLD JM et al.: Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin. PharmacoL Then (1996) 60(1):25–33.
  • AZAZ-LIVSHITS U, DANENBERG HD: Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopychiatry (1997) 30(6):274–275.
  • SCHUG BS, BRENDEL E, CHANTRAINE E et aL: The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br. J Gun. PharmacoL (2002) 53(6):582–588.
  • PASHKO S, SIMONS WR, SENA MM, STODDARD ML: Rate of exposure to theophylline-drug interactions. Ther. (1994) 16(6): 1068–1077.
  • STRINGER KA, MALLET J, CLARKE M, LINDENFELD JA: The effect of three different oral doses of verapamil on the disposition of theophylline. Eur. J. Clin. PharmacoL (1992) 43(1):35–38.
  • JOHNSON BF, CHENG SL, VENITZ J: Transient kinetic and dynamic interactions between verapamil and dofetilide, a Class III antiarrhythmic. J. Clin. PharmacoL (2001) 41(11):1248–1256.
  • BAUER LA, SCHUMOCK G, HORN J, OPHEIM K: Veraparnil inhibits ethanol elimination and prolongs the perception of intoxication. Clin. PharmacoL Then (1992) 52(1):6–10.
  • RUBIN AS, ZABLOCKI AD: Hyperkalemia, verapamil, and dantrolene. Anesthesiology (1987) 66(2):246–249.
  • KAPLAN NM, GIFFORD RW Jr: Choice of initial therapy for hypertension. JAMA (1996) 275(20):1577–1580.
  • HASFORD J, MIMRAN A, SIMONS WR: A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum. Hypertens. (2002) 16:569–575.
  • CONLIN PR, GERTH WC, FOX J, ROEHM JB, BOCCUZZI SJ: Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Ther. (2001) (23):1999–2010.
  • CHOBANIAN AV: Control of hypertension - an important national priority. N. EngL J. Med. (2001) 345(7):534–535.
  • ••Illustrative short review of the prevalenceand clinical relevance of uncontrolled hypertension.
  • CLELAND JG, COHEN-SOLAL A, AGUILAR JC et aL; IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 360(9346):1631–1639.
  • FARNETT L, MULROW CD, LINN WD, LUCEY CR, TULEY MR: The J-curve phenomenon and the treatment of hypertension. JAMA (1991) 265(4):489–495.
  • VOKO Z, BOTS ML, HOFMAN A, KOUDSTAAL PJ, WITTEMAN JC, BRETLER MM: J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension (1999) 34(6):1181–1185.
  • BOUTITIE F, GUEYFFIER F, POCOCK S, FAGARD R, BOISSEL JP: J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann. Intern. Med. (2002) 136(6):438–448.
  • NO AUTHORS LISTED: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA (1991) 265(24):3255–3264.
  • ••Landmark trial demonstrating superiorityof chlortalidone over placebo for prevention of stroke.
  • DAHLOF B, LINDHOLM LH, HANSSON L, SCHERSTEN B, EKBOM T, WESTER PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet (1991) 338(8778):1281–1285.
  • ••Landmark trial demonstrating superiority of antihypertensive treatment over placebo for the reduction of cardiovascular morbidity and mortality.
  • LEAPE LL: Reporting of adverse events. N EngL J Med. (2002) 347(20):1633–1638.
  • ••Reviews the uncertainties associated withreporting of adverse events.
  • RUDD P: Partial compliance: implications for clinical practice. Cardiovasc. PharmacoL (1993) 22(Suppl. A):S1–55.
  • ROSES AD: Pharmacogenetics and future drug development and delivery. Lancet (2000) 355(9212):1658–1661.
  • ••Review of pharmacogenetics.
  • BRADFORD LD, KIRLIN WG: Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int. J NeuropsychopharmacoL (1998) 1(2): 173–185.
  • SHIMADA T, YAMAZAKI H, MIMURA M et aL: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. PharmacoL Exp. Ther. (1994) 270(1):414–423.
  • MURPHY MP, BEANMAN ME, CLARK LS et aL: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics (2000) 10(7):583–590.
  • WIKSTRAND J, HJALMARSON A, WAAGSTEIN F et aL: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J. Am. Coll. CardioL (2002) 40(3):491–498.
  • ••Landmark trial demonstrating the efficacyof metoprolol in patients with heart failure.
  • BROWN WV: Cholesterol lowering in atherosclerosis. Am. J. CardioL (2000) 86(4B):H29–H32.
  • YEO KR, YEO WW, WALLIS EJ, RAMSAY LE: Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br. J. Clin. PharmacoL (1999) 48(4):610–615.
  • SASEEN JJ, CARTER BL, BROWN TE: Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension (1996) 28(1):109–114.

Websites

  • http://www.cdc.govinchs/fastats/drugs.htm NO AUTHORS LISTED: NCHS-FASTATS — Drug Use Health Facts.
  • •Valuable intemet page on the statistics of drug prescriptions and use in the US.
  • http://www.ncbi.nkn.nih.gov/entrez/query.fcgi PubMed/MedLine website.
  • http://www.fda.gov/cder FDA website.
  • http://www.fda.gov/medwatch/safety.htm FDA website.
  • http://www.bfarm.de/gb_ver/drugs German drug authority BfArM.
  • http://medicine.iupui.edu/flockhart
  • •Very useful intemet page on GYP metabolism of drugs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.